CASE REPORT

Multiple Placental Infarcts in a Pregnant Woman with Essential Thrombocythemia

Yoko Edahiro¹, Jun Ando¹, Toshifumi Suzuki², Yuki Fukumura³, Azuchi Masuda¹, Shiori Sakayori², Jun Takeda², Yojiro Maruyama², Shintaro Makino², Atsuo Itakura² and Norio Komatsu¹

Abstract:
Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis, mainly occur in older patients, but have also been reported in younger patients. A “second peak” occurs in female patients in their thirties, particularly in ET; thus, the management of pregnancy is often discussed.

We herein present the case of a 33-year-old woman with a high platelet count and multiple placental infarcts during delivery who was subsequently diagnosed with ET. Although there are no worldwide guidelines for the management of MPNs in pregnancy, the risk of thrombosis is markedly increased in these patients, and antithrombotic therapy should be considered.

Key words: myeloproliferative neoplasms, essential thrombocythemia, pregnancy, placental infarcts, aspirin, low-molecular-weight heparin

(Intern Med 57: 3647-3650, 2018)
(DOI: 10.2169/internalmedicine.1311-18)

Introduction

Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), are clonal disorders characterized by an overproduction of terminally differentiated hematopoietic cells. MPNs mainly affect the elderly, but can also occur in women of childbearing age, especially concerning ET. The risks of miscarriage and other complications during pregnancy in patients with MPNs are higher than those in the general population. Therefore, management of MPNs during pregnancy may require special considerations.

We report a 33-year-old woman with high platelet counts showing multiple placental infarcts upon delivery, and subsequently diagnosed with ET. Administration of aspirin or heparin in pregnant ET patients has been reported to improve live birth rates. Our report reconfirms the need of antithrombotic therapy in ET patients during pregnancy.

Case Report

A 33-year-old woman at 32 weeks of gestation was referred to our hospital with a high platelet count. The medical record from her first pregnancy, which occurred six years previously, showed a normal platelet count, protein C activity, and antithrombin III level. The levels of total protein S antigen and free protein S antigen were slightly below normal, presumably because of pregnancy (1, 2), and lupus anticoagulant and anti-cardiolipin antibodies were both negative. However, two months prior to her second pregnancy, a medical examination revealed a high platelet count that was not treated. Since the non-stress test (NST) showed a loss of variability, she was immediately admitted to our hospital. The patient also had high blood pressure and proteinuria, and was diagnosed with hypertensive disorders of pregnancy. A hematogram showed a platelet count of 1,002×

¹Department of Hematology, Juntendo University School of Medicine, Japan, ²Department of Obstetrics and Gynecology, Juntendo University School of Medicine, Japan and ³Department of Human Pathology, Juntendo University School of Medicine, Japan

Received: April 2, 2018; Accepted: April 26, 2018; Advance Publication by J-STAGE: August 10, 2018
Correspondence to Dr. Yoko Edahiro, yedahiro@juntendo.ac.jp
10^9/L, a white blood cell count of 8.5×10^9/L, and a hemoglobin level of 13.0 g/dL (Table). Treatment with heparin (10,000 U/day) was initiated in order to prevent microthrombosis. At three days after her admission, fetal variability disappeared and NST showed late decelerations. A non-reassuring fetal status was diagnosed and emergency cesarean section was performed. The baby weighed 1,580 g and had Apgar scores of 5 and 7 at 1 and 5 minutes, respectively, and was therefore admitted to the neonatal care unit. Multiple placental infarcts were observed (Fig. 1). After delivery, the patient was treated with low-molecular-weight heparin (4,000 U), followed by heparin (10,000 U/day) for 6 weeks.

At two months after delivery, a bone marrow assessment revealed an elevated number of enlarged megakaryocytes with a slight increase in reticulin fibers, which was classified as the MF-1 grade (Fig. 2). No genetic mutations of JAK2, MPL, or CALR were detected; thus, the patient was diagnosed with triple-negative ET.

Discussion

The incidence of hemorrhagic and thromboembolic complications is high in patients with MPNs; thus, the main treatment strategy aims to prevent these events. Cytoreduc-

Table. Laboratory Findings on Admission.

| Peripheral blood | Blood chemistry | Serological test |
|------------------|-----------------|-----------------|
| WBC 8.5×10^9/L  | TP 6.8 g/dL     | CRP 0.5 mg/dL   |
| Neu 77 %        | Alb 3.1 g/dL    | Fe 109 μg/dL    |
| Lym 18 %        | AST 22 U/L      | TIBC 533 μg/dL  |
| Mono 4 %        | ALT 17 U/L      | ferritin 39 ng/mL|
| Eosi 1 %        | ALP 639 U/L     | Epo 6.8 mIU/mL  |
| RBC 4.3×10^12/L | γGTP 16 U/L     |                |
| Hb 13 g/dL      | LDH 202 U/L     | Urinalysis      |
| Hct 36.8 %      | T-Bil 0.4 mg/dL | Protein (3+)    |
| Plt 1,002×10^9/L| BUN 23 mg/dL    | Sugar (-)       |
| Reti 22 %       | Cre 0.7 mg/dL   | Occult blood (-) |
| PT(INR) 0.91    | Na 135 mEq/L    |                |
| APTT 40.7/36.0 sec | Cl 103 mEq/L |
| FIB 546 mg/dL   |                |                |
| FDP 5.7 μg/mL   | vWF 177 %       |                |

Reti: reticulocyte, vWF: von Willebrand factor, Epo: erythropoietin

Figure 1. A gross view of the placenta. The fetal side of the placenta (A) showed collapsed amniotic vessels and a cut section (B) showed multiple infarcts (arrow heads).

Figure 2. A histopathological view of the bone marrow (aspiration biopsy) showed slightly hypercellular bone marrow with scattered enlarged megakaryocytes.
tion therapy using hydroxyurea, anagrelide, or other drugs is recommended for high-risk ET patients, defined by >60 years of age and/or a history of a previous thrombotic event. Cytoreductive therapy is also recommended for patients with platelet counts of >1,500x10^9/L because they have a high risk of bleeding. In contrast, young patients with no cardiovascular risk factors and a low risk of thrombosis, such as the patient in the present case, are often not treated. However, a systemic review showed that the risk of developing thrombotic events was two-fold higher in patients with the JAK2 V617F mutation (3); thus, antithrombotic therapy has recently been applied to the treatment of young patients with JAK2 mutations.

We previously conducted a retrospective analysis of Japanese patients with MPNs and the findings obtained showed that the mean ages of MPN patients with PV, ET, and PMF were 66.4, 57.2, and 66.3 years, respectively, suggesting that MPNs mainly occur in elderly patients (4). However, MPNs have also been reported in young patients; we found a “second peak” in female ET patients in their thirties (4). Thus, an increase in the risk of ET with pregnancy has frequently been discussed.

Among patients with ET, 50-60%, 15-30%, and 5% harbor the JAK2 V617F, CALR, and MPL mutations, respectively. The remaining patients are referred to as triple-negative ET patients because they do not carry JAK2, CALR, or MPL mutations. More than 30% of young ET patients in the “second peak” have been found to be triple-negative (5). These triple-negative ET patients have been reported to have lower hemoglobin levels, a lower leukocyte count, and longer survival (6). The risk of thrombotic events in triple-negative ET patients was shown to be significantly lower than that in patients with JAK2 mutations, even in a multivariable analysis adjusted for age and a history of thrombosis (7).

Recent reports have shown the increased risk of maternal and fetal complications, including hypertensive disorders, in patients with MPNs (8-11). The risk of fetal loss in pregnant ET patients was previously reported to be 3- to 4-fold higher than that in the general population (10). Studies conducted in the USA, Italy, and Finland showed that the rate of live births was approximately 60%, while abortion in the first trimester occurred in approximately 33% of pregnancies (67%). The presence of the JAK2 V617F mutation in ET patients was identified as an independent risk factor for pregnancy complications (10). In contrast, the findings of a study by the Mayo Clinic demonstrated that JAK2 V617F-positive and -negative patients had a similar rate of pregnancy loss (12). Indeed, the present patient with triple-negative ET developed multiple placental infarcts, suggesting the need for antithrombotic therapy, not only for patients with JAK2 mutations, but also for pregnant JAK2-negative patients.

Although there are currently no worldwide guidelines for pregnant MPN patients, the European LeukemiaNet guidelines recommend the use of low-dose aspirin for patients with low-risk pregnancies, and low-molecular-weight heparin for those with high-risk pregnancies with a previous history of a major thrombotic event and/or severe pregnancy complications (13). Alimam et al. reported the outcomes of 58 pregnant women (56 singleton pregnancies and 1 twin pregnancy) with MPNs, among whom 88% received aspirin during the index pregnancy and 41% were additionally prescribed low-molecular-weight heparin (14). Fifty-eight pregnancies resulted in live births, one in miscarriage, and one in a stillbirth. The rate of miscarriage was 1.7%, which was lower than that previously reported, and may have been due to the high rate at which aspirin was administered. The findings of another study conducted in the USA revealed that the rates of pregnancy loss among patients who received aspirin was 21%, while that among patients who did not receive aspirin was 75%, indicating a salutary role for aspirin therapy among pregnant ET patients (12). Niittyvuopio et al. also reported that all 13 pregnancies treated with aspirin exhibited no complications during pregnancy, whereas 18 out of 27 pregnancies (67%) without any treatment had at least one pregnancy-related complication and 15 resulted in miscarriage (15).

High rates of placental infarction due to thrombosis in ET patients have been reported (16), and this seems to be the most consistent pathogenesis of the pregnancy failures (17). Additionally, in the present case, the patient’s condition was also complicated by hypertensive disorders of pregnancy, which is a major cause of placental infarction.

In conclusion, we presented the case of a pregnant ET patient. Delivery resulted in a live birth; however, the patient was complicated by placental infarction and the infant was born with a low birth weight. The use of aspirin or heparin has been reported to increase the live birth rate among ET patients; thus, we strongly recommend the administration of antithrombotic therapy to ET patients during their pregnancy, even if the patient’s condition is categorized as low-risk.

The authors state that they have no Conflict of Interest (COI).

References

1. Said JM, Ignjatovic V, Monagle PT, Walker SP, Higgins JR, Brennecke SP. Altered reference ranges for protein C and protein S during early pregnancy: implications for the diagnosis of protein C and protein S deficiency during pregnancy. Thromb Haemost 103: 984-988, 2010.
2. Pintao MC, Ribeiro DD, Bezemter ID, et al. Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study. Blood 122: 3210-3219, 2013.
3. Lussana F, Caberlon S, Pagani C, Khampisae PW, Buller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 124: 409-417, 2009.
4. Edahiro Y, Morishita S, Takahashi K, et al. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol 99: 625-634, 2014.
5. Shirane S, Araki M, Morishita S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica 100: e46-e48, 2015.
6. Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocytopenia. Leukemia 28: 2300-2303, 2014.
7. Gangat N, Wassie EA, Lasho TL, et al. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol 94: 31-36, 2015.
8. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 129: 293-306, 2005.
9. Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev 22: 235-245, 2008.
10. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 110: 485-489, 2007.
11. Randi ML, Bertozzi I, Rumi E, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol 89: 306-309, 2014.
12. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol 82: 350-353, 2009.
13. Barbu T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29: 761-770, 2011.
14. Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol 175: 31-36, 2016.
15. Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol 73: 431-436, 2004.
16. Pagliaro P, Arrigoni L, Muggiasca ML, Poggio M, Russo U, Rossi E. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol 53: 6-10, 1996.
17. Griesshammer M, Heimpel H, Pearson TC. Essential thrombocythemia and pregnancy. Leuk Lymphoma 22(Suppl 1): 57-63, 1996.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).